Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

[1]  N. Leidy,et al.  Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. , 2014, Annals of the American Thoracic Society.

[2]  J. Wedzicha,et al.  Minimal clinically important differences in pharmacological trials. , 2014, American journal of respiratory and critical care medicine.

[3]  “Actavis” , 2013, IIC - International Review of Intellectual Property and Competition Law.

[4]  A. Church,et al.  Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. , 2013, Respiratory medicine.

[5]  E. Bateman,et al.  Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study , 2013, European Respiratory Journal.

[6]  N. Leidy,et al.  Patient-reported Outcome (PRO) Measures for Clinical Trials of COPD: The EXACT and E-RS , 2013, COPD.

[7]  D. Tashkin,et al.  Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease , 2013, Respiratory Research.

[8]  M. Cazzola,et al.  Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease , 2013, Expert opinion on pharmacotherapy.

[9]  K. Rabe,et al.  Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. , 2013, Chest.

[10]  M. R. Maleki-Yazdi,et al.  Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD , 2012 .

[11]  Mario Cazzola,et al.  Pharmacology and Therapeutics of Bronchodilators , 2012, Pharmacological Reviews.

[12]  E. Kerwin,et al.  Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I) , 2012, COPD.

[13]  E. Bateman,et al.  Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study , 2012, European Respiratory Journal.

[14]  E. Kerwin,et al.  Novel Combination Of Glycopyrrolate And Formoterol MDI (GFF-MDI) Provides Superior Bronchodilation Compared To Its Components Administered Alone, Tiotropium DPI, And Formoterol DPI In A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study In Patients With COPD , 2011, ATS 2011.

[15]  M. Cazzola,et al.  β2‐adrenoceptor agonists: current and future direction , 2011, British journal of pharmacology.

[16]  Marie Westwood,et al.  Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review , 2011, Respiratory research.

[17]  N. Leidy,et al.  Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. , 2011, American journal of respiratory and critical care medicine.

[18]  I. Kirsch,et al.  Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome , 2010, PloS one.

[19]  N. Leidy,et al.  Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  M Cazzola,et al.  Symptom variability in patients with severe COPD: a pan-European cross-sectional study , 2010, European Respiratory Journal.

[21]  L. Fabbri,et al.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents , 2010, Respiratory research.

[22]  S. Sentellas,et al.  Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  M. Partridge,et al.  Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey , 2009, Current medical research and opinion.

[24]  E. G. Gil,et al.  Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. , 2009, International journal of clinical pharmacology and therapeutics.

[25]  J. Donohue.  Minimal Clinically Important Differences in COPD Lung Function , 2005, COPD.

[26]  D. Benhamou,et al.  Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). , 2001, Respiratory medicine.

[27]  V. Preedy,et al.  Patient Reported Outcome , 2010 .

[28]  S. Hurd,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[29]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[30]  B. Smith,et al.  Long-acting beta2-agonists for chronic obstructive pulmonary disease. , 2000, The Cochrane database of systematic reviews.